PathSensors, Inc. – Trademark Portfolio
Entity Type: 03
PathSensors, Inc. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 7 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include CANARY, BIOFLASH, MAILGUARD, and PATHSENSORS. The owner is based in Baltimore, MD.
701 E. Pratt Street
Baltimore, MD 21202
Showing of trademarks Trademarks
Trademark Classifications
PathSensors, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does PathSensors, Inc. have?
PathSensors, Inc. has 8 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 abandoned, 1 cancelled.
What trademark classes does PathSensors, Inc. file in?
PathSensors, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are PathSensors, Inc.'s most well-known trademarks?
PathSensors, Inc.'s registered trademark portfolio includes well-known marks such as CANARY, BIOFLASH, MAILGUARD, and PATHSENSORS. These are among 6 currently registered trademarks in the portfolio.
What is PathSensors, Inc.'s trademark registration success rate?
PathSensors, Inc. has a 75% trademark registration rate, with 6 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.